Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
11
×
fda
11
×
national blog main
life sciences
clinical trials
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
wisconsin blog main
wisconsin top stories
boston
cancer
investing
medical device
pfizer
teva pharmaceutical
abbvie
alnylam pharmaceuticals
What
drug
11
×
fda
approved
medicine
new
approval
ago
alnylam
big
bio
class
companies
disease
europe
interference
make
medicines
migraine
news
oks
pharmaceuticals
rna
rnai
roundup
second
therapeutics
weeks
won
year
alzheimer’s
announced
annual
approves
arguments
assessed
attention
bacteria
based
battle
biopharma
Language
Current search:
fda
×
drug
×
drugs
×
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug